首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Structure-Activity Relationships of Different β-Lactam Antibiotics against a Soluble Form of Enterococcus faecium PBP5 a Type II Bacterial Transpeptidase
【2h】

Structure-Activity Relationships of Different β-Lactam Antibiotics against a Soluble Form of Enterococcus faecium PBP5 a Type II Bacterial Transpeptidase

机译:不同的β-内酰胺类抗生素对屎肠球菌PBP5(一种II型细菌转肽酶)的可溶性形式的构效关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Penicillin-binding proteins (PBPs) catalyze the essential reactions in the biosynthesis of cell wall peptidoglycan from glycopeptide precursors. β-Lactam antibiotics normally interfere with this process by reacting covalently with the active site serine to form a stable acyl-enzyme. The design of novel β-lactams active against penicillin-susceptible and penicillin-resistant organisms will require a better understanding of the molecular details of this reaction. To that end, we compared the affinities of different β-lactam antibiotics to a modified soluble form of a resistant Enterococcus faecium PBP5 (Δ1-36 rPBP5). The soluble protein, Δ1-36 rPBP5, was expressed in Escherichia coli and purified, and the NH2-terminal protein sequence was verified by amino acid sequencing. Using β-lactams with different R1 side chains, we show that azlocillin has greater affinity for Δ1-36 rPBP5 than piperacillin and ampicillin (apparent Ki = 7 ± 0.3 μM, compared to 36 ± 3 and 51 ± 10 μM, respectively). Azlocillin also exhibits the most rapid acylation rate (apparent k2 = 15 ± 4 M−1 s−1). Meropenem demonstrates an affinity for Δ1-36 rPBP5 comparable to that of ampicillin (apparent Ki = 51 ± 15 μM) but is slower at acylating (apparent k2 = 0.14 ± 0.02 M−1 s−1). This characterization defines important structure-activity relationships for this clinically relevant type II transpeptidase, shows that the rate of formation of the acyl-enzyme is an essential factor determining the efficacy of a β-lactam, and suggests that the specific side chain interactions of β-lactams could be modified to improve inactivation of resistant PBPs.
机译:青霉素结合蛋白(PBPs)催化从糖肽前体生物合成细胞壁肽聚糖中的重要反应。 β-内酰胺抗生素通常通过与活性位点丝氨酸共价反应形成稳定的酰基酶来干扰这一过程。对对青霉素敏感和耐青霉素的生物有活性的新型β-内酰胺的设计将需要对该反应的分子细节有更好的了解。为此,我们比较了不同的β-内酰胺类抗生素与耐药性粪便肠球菌PBP5(Δ1-36rPBP5)的修饰可溶性形式的亲和力。可溶性蛋白Δ1-36rPBP5在大肠杆菌中表达并纯化,并通过氨基酸测序验证了NH2末端蛋白序列。我们使用具有不同R1侧链的β-内酰胺显示,阿洛西林对Δ1-36rPBP5的亲和力高于哌拉西林和氨苄西林(表观Ki = 7±0.3μM,而分别为36±3和51±10μM)。 Azlocillin还表现出最快的酰化速率(表观k2 = 15±4 M -1 s -1 )。美洛培南对Δ1-36rPBP5的亲和力与氨苄西林相当(表观Ki = 51±15μM),但酰化速度较慢(表观k2 = 0.14±0.02 M -1 s - 1 )。该表征为该临床相关的II型转肽酶定义了重要的构效关系,表明酰基酶的形成速率是决定β-内酰胺功效的重要因素,并表明β的特定侧链相互作用可以修饰β-内酰胺以改善抗性PBP的失活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号